RVP

Business Context and Reporting Period

Company: Retractable Technologies, Inc. (RTI)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: RTI designs, manufactures, and markets patented safety medical products, primarily the VanishPoint® automated retraction syringe, designed to prevent needlestick injuries. The company operates in a market dominated by Becton Dickinson (BD), against which RTI is actively litigating for patent infringement and antitrust violations. Approximately 74% of finished products are manufactured by a single Chinese supplier, Double Dove.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total sales increased 6.1% to $27.9 million, driven by higher average sales prices and increased unit volumes (3.1% increase), particularly in the 1cc syringe category. Domestic sales comprised 83.3% of revenue.
• Margin Compression: Gross profit margin declined from 30.4% to 29.5% due to higher manufacturing costs, including a $0.005 per unit price increase from the Chinese supplier (Double Dove) in Q4 2008.
• Operating Expenses: Total operating expenses rose to $18.7 million (from $17.9 million). General and administrative costs increased significantly due to higher legal fees associated with ongoing litigation against BD, Abbott, and others. Sales and marketing expenses decreased due to reduced travel and trade show costs.
• Liquidity Decline: Cash and cash equivalents decreased by approximately $7.2 million to $33.3 million, primarily due to operating losses and increased legal expenses. Net cash used in operating activities was $5.9 million.
• Debt Increase: Long-term debt increased to $6.1 million, reflecting a new $4.2 million construction line of credit used to expand warehouse and office facilities.

Guidance, Outlook, and Risks

• Market Access: Management continues to face significant barriers to market entry due to exclusive contracts held by competitor BD. The company relies on litigation, international sales, and alternate care markets to drive volume.
• Litigation Status:
  • vs. BD: Trial scheduled for October 2009 regarding patent infringement and antitrust claims. Legal expenses are expected to decrease significantly post-trial.
  • vs. Abbott: Trial scheduled for January 2010 regarding breach of contract and fraud.
  • vs. OMI & SMI: Ongoing patent infringement suits with trials set for late 2009.
• Royalties: A licensing agreement with BTMD (China) expired in May 2008. While the facility is complete, expected royalty payments have not yet commenced due to regulatory requirements. Management expects royalties to begin once requirements are met but cannot predict the date.
• Liquidity Risk: If market access remains limited and BTMD royalties do not materialize, the company may need to implement cost-cutting measures, including workforce reductions and deferral of royalty payments.
• Patent Expiration: Principal U.S. patents protecting the core technology are set to expire in May 2015.

Investor Verification Checklist

• Litigation Outcomes: Verify the status and potential financial impact of the BD trial (Oct 2009) and Abbott trial (Jan 2010), as these are critical to future market access and cash flow.
• BTMD Royalties: Confirm the timeline for the commencement of royalty payments from the Chinese licensee, as this is a key anticipated revenue stream.
• Supplier Concentration: Assess the risk associated with 74% of production being sourced from a single Chinese manufacturer (Double Dove) and the feasibility of ramping up domestic production if supply is disrupted.
• Cash Burn Rate: Monitor the $33.3 million cash balance against the $10.4 million annual operating loss and ongoing legal costs to determine runway without additional financing.
• Preferred Stock Arrears: Note the $13.9 million in cumulative preferred dividends in arrears, which must be paid before any common stock dividends can be declared.